生物技术

A New Turning Point in Biotechnology: The Rapid Growth of AI Integration and Personalized Medicine by 2025

Editor
5 分钟阅读

Industry Innovation Driven by AI and Biotechnology Integration

In 2025, the biotechnology industry is reaching a historic turning point through its integration with artificial intelligence. The global biotech market size is projected to grow from $980 billion in 2024 to $1.2 trillion in 2025, a 22.4% increase, according to McKinsey Global Institute. The key drivers of this rapid growth are the commercialization of AI-based drug development platforms and the full-scale market entry of personalized therapies. Notably, technologies such as protein structure prediction and drug-target interaction analysis using machine learning algorithms are reducing new drug development timelines from the traditional 10-15 years to 5-7 years, prompting a paradigm shift across the pharmaceutical industry.

A New Turning Point in Biotechnology: The Rapid Growth of AI Integration and Personalized Medicine by 2025

South Korea’s biotech ecosystem plays a significant role in these global trends. Samsung Biologics, headquartered in Incheon, recorded a 34% year-on-year increase in revenue, reaching 2.8 trillion won by the third quarter of 2025, capturing a 17.3% share of the global biopharmaceutical contract manufacturing (CMO) market. The company has introduced an AI-based production optimization system, improving production efficiency by 28%, which serves as a key competitive advantage in meeting global pharmaceutical companies’ demands for cost reduction. Meanwhile, Celltrion, located in Songdo, has established an AI-driven quality management system in the biosimilar sector, increasing FDA approval success rates from 72% to 89%.

Major U.S. pharmaceutical companies are also actively adopting AI technologies. Johnson & Johnson, headquartered in New Jersey, announced a $4.7 billion investment in AI-based drug development by 2025, accounting for 31% of its total R&D budget. The company’s AI platform is currently analyzing 134 candidate substances, with 23 entering Phase 1 clinical trials. Similarly, Pfizer, based in New York, identified eight new therapeutic candidates in the first half of 2025 through its AI-based drug discovery platform, a 60% increase from previous figures. AI plays a crucial role in Alzheimer’s treatment development, improving clinical trial success rates from 12% to 23%.

The rapid growth of the Precision Medicine market is also noteworthy. The global personalized medicine market is valued at $284 billion by 2025, with an annual growth rate of 13.8%. Roche, headquartered in Basel, Switzerland, holds a leading position in this field. Roche’s personalized cancer therapy portfolio recorded $18.9 billion in sales by the third quarter of 2025, accounting for 42% of total revenue. The company’s HER2-positive breast cancer treatment, Kadcyla, improved treatment response rates from 76% to 84% through an AI-based patient selection system.

Accelerating Commercialization of Gene Editing and Cell Therapy

The commercialization of CRISPR gene editing technology is emerging as another growth driver for the biotech industry in 2025. The global CRISPR market size increased by 31% to $8.9 billion in 2025, with Grand View Research forecasting an annual growth rate of 28.5% through 2030. This growth is driven by the accelerated FDA approval of rare genetic disorder treatments. In 2025 alone, seven CRISPR-based therapies received FDA approval, more than doubling from three in 2024.

In the Cell Therapy sector, CAR-T therapies are expanding their application scope, driving market growth. The global CAR-T cell therapy market is valued at $12.7 billion by 2025, rapidly growing as indications expand from hematologic cancers to solid tumors. Moderna, headquartered in Massachusetts, is leading innovation in the personalized cancer vaccine field using mRNA technology. The company’s personalized cancer vaccine, mRNA-4157, showed a 44% reduction in recurrence rates in Phase 3 trials for melanoma patients, with commercialization targeted for 2026.

Advancements in gene sequencing technology are also accelerating the spread of personalized treatments. Illumina, based in San Diego, California, launched the NovaSeq X Plus next-generation sequencing (NGS) platform in 2025, reducing the cost of whole-genome sequencing to $200. This is 0.000007% of the $2.7 billion cost at the completion of the Human Genome Project in 2003, making the popularization of personalized treatments a reality. Illumina’s third-quarter 2025 revenue increased by 18% year-on-year to $1.24 billion, with oncology sector revenue surging by 41%.

Korean biotech companies are actively participating in these global trends. Celltrion initiated Phase 2 clinical trials for its CAR-T cell therapy CT041 in the second half of 2025, marking the first self-developed CAR-T therapy by a Korean company. The company invested 280 billion won in developing this therapy, targeting commercialization by 2028. Additionally, Samsung Biologics is preparing to enter the global cell therapy CMO market by establishing a dedicated facility for cell therapy production at the Songdo Bio Campus.

The convergence of digital healthcare and biotechnology is also creating new market opportunities. The predictive healthcare market, combining real-time biometric data collection through wearable devices with AI analysis, is rapidly growing, shifting the paradigm to preventive, personalized treatments. The global digital healthcare market is valued at $659 billion by 2025, emerging as a new revenue source for biotech companies. The effectiveness of digital-bio convergence solutions in managing diabetes and cardiovascular diseases has been demonstrated, leading to expanded insurance coverage.

Changes in the regulatory environment are also supporting the growth of the biotech industry. The FDA announced new guidelines for AI-based drug development in 2025, streamlining the approval process. As a result, the clinical trial approval period for AI-based therapies has been reduced from 18 months to 12 months, positively impacting funding and development timelines for biotech startups. The European Medicines Agency (EMA) has implemented similar regulatory easing measures, accelerating the growth of the global biotech market.

The biotechnology industry has entered a new growth trajectory in 2025 through the integration of AI, personalized medicine, and the commercialization of gene editing technologies. With the global market size surpassing $1.2 trillion, technological innovation and increased investment by major companies, including those in Korea, continue. The improved success rates and shortened development timelines of AI-based drug development enhance overall industry efficiency, providing patients with more effective and personalized treatment options. As regulatory environments continue to improve and the integration with digital healthcare expands, the biotech industry is expected to lead the digital transformation of the entire healthcare ecosystem.

The information presented in this post is for general informational purposes only and should not be construed as investment advice. Please consult a financial advisor before making investment decisions.

#SamsungBiologics #Celltrion #Johnson & Johnson #Pfizer #Roche #Moderna #Illumina

Editor

Leave a Comment

Related Articles

生物技术创新的新转折点:2025年精准医学与基因治疗市场的快速增长

2025年,生物技术产业正在经历人工智能与基因编辑技术融合带来的前所未有的创新。特别是在韩国和美国为中心的精准医学市场,以每年15%的增长率引发了新的投资热潮。

生物技术产业的AI融合与个性化医疗的未来:2026年市场分析

人工智能与生物技术的融合正在开启个性化医疗的新时代。截至2026年,全球生物技术市场已增长至1.2万亿美元,基于AI的新药开发和基因治疗领域的创新变革正在加速。

生物技术革命的新转折点:AI驱动的药物开发与精准医学引领的2026年生物技术产业分析

截至2026年2月,全球生物技术产业正因人工智能与精准医学技术的融合而迎来历史上最为动态的变革时期。根据市场研究机构麦肯锡的最新报告,预计到2026年,全球生物技术市场规模将达到1.24万亿美元,这意味着相较于2023年,年均增长率为18.3%。尤其是AI驱动的药物发现领域,较去年增长了42%,扩大至680亿美元规模,这种增长趋势表明传统药物开发流程正在发生根本性变化。 这种变化的核心在于计算机辅助药物设计和利用机器学习算法进行分子结构预测的技术。英国的DeepMind开发的AlphaFold系统到2025年底已预测了超过2亿个蛋白质结构,这使得全球制药公司的研发效率平均提高了35%。总部位于美国波士顿的Moderna宣布,通过结合其mRNA平台与AI技术,将新药开发周期从传统的10-15年缩短至5-7年。这一速度比行业平均快40%,仅年度研发费用节省效果就达到约23亿美元。 韩国的生物技术产业也在紧跟这一全球趋势,快速增长。总部位于仁川的三星生物制剂在2025年第四季度实现了1.82万亿韩元的销售额,同比增长28.4%。特别是其运营的松岛生物集群已扩展至年产能62万升,成为全球最大的生物药品合同生产(CMO)设施。位于松岛的Celltrion也通过扩大其生物仿制药组合,在2025年实现了3.21万亿韩元的年销售额,占全球生物仿制药市场的6.8%。 在精准医学领域,基因组分析技术的飞跃性发展备受关注。到2025年,全基因组测序(Whole Genome Sequencing)的成本下降至600美元水平,个性化治疗方法的开发开始全面展开。总部位于美国加州南旧金山的Gilead Sciences通过其CAR-T细胞治疗药物Yescarta开发了根据患者基因谱量身定制的治疗方案,将治疗成功率提高到78%。这一数值比现有标准治疗方法的成功率52%高出26个百分点,被认为是精准医学方法有效性的证明。 AI驱动药物开发的市场创新与竞争格局 在利用人工智能进行药物开发的领域,传统制药公司与AI专业生物科技初创公司之间展开了激烈竞争。总部位于瑞士巴塞尔的Roche在2025年投资17亿美元于AI药物发现领域,并通过其子公司Foundation Medicine开发肿瘤学领域的精准医学解决方案。其AI平台目前在230多个临床试验中被使用,其中42个项目将在2026年上半年进入临床三期。 总部位于美国纽约的Pfizer通过其数字创新部门建立了基于机器学习的分子设计平台。该平台将分子筛选速度提高了15倍,并将新药候选物的发现成功率从23%提升至41%。特别是在阿尔茨海默病治疗项目中,利用AI算法成功识别了三个此前未被发现的新靶蛋白。基于这些成就,Pfizer宣布计划在2026年将AI相关研发投资较去年增加35%,达到28亿美元。 与此同时,瑞士的Novartis通过其AI计划专注于罕见病治疗药物的开发。其开发的AI平台“Neptune”专注于分析罕见病患者数据,发现此前未知的疾病机制。2025年,通过Neptune平台发现了17个新的罕见病治疗靶点,其中5个已进入临床前阶段。Novartis的CEO Vas Narasimhan表示:“通过AI技术,我们能够为罕见病患者提供新的希望”,并计划在未来三年内投资45亿美元于AI罕见病研究。 DSP-1181是一种借助AI设计并进入强迫症1期研究的候选药物。然而,根据Sumitomo Pharma的官方说明,该药物未达到1期研究的预期标准,因此开发已经终止。它并未获得FDA批准。 精准医学与个性化治疗的商业化加速 根据FDA的说明,伴随诊断可提供安全、有效使用相应治疗产品所需的信息。疗效和安全性数据必须针对具体检测、药物、适应证和试验进行核实,不能据此推断Imbruvica的反应率普遍从67%升至84%,或不良反应减少32%。 EDIT-101在14名LCA10患者中开展的是1/2期试验。Editas的申报文件称,在2022年11月的分析中,14人中有3人达到公司设定的复合反应标准,公司于2023年1月暂停继续招募。随后发表的2024年同行评议论文报告,14人中有11人在四项结局指标中的至少一项达到具有临床意义的改善,6人在至少两项指标上达到这一标准。由于不同指标的结果并不相同,不能把该研究表述为2期或3期试验,也不能概括为73%或87%的统一视力改善率。 在细胞治疗领域,CAR-T细胞治疗方法的应用范围已从血液癌症扩展到实体瘤。总部位于美国新泽西州普林斯顿的Johnson…